title: Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis.
abstract: Juvenile dermatomyositis (JDM) is the most common form of juvenile idiopathic inflammatory myopathy. We report a child with steroid-dependent JDM refractory to hydroxychloroquine and subcutaneous methotrexate who experienced systemic reactions to intravenous immunoglobulin and was successfully treated with subcutaneous immunoglobulin. This form of therapy has been shown to be safe, has a very low rate of adverse effects, does not require hospital admission, reduces the number of missed school days, and decreases the costs associated with treatment.
authors.affiliation: Section of Pediatric Rheumatology and jaime.inocencio@salud.madrid.org.
authors.forename: Jaime
authors.initials: J
authors.lastname: de Inocencio
authors.affiliation: Section of Pediatric Rheumatology and.
authors.forename: Eugenia
authors.initials: E
authors.lastname: Enríquez-Merayo
authors.affiliation: Section of Pediatric Rheumatology and.
authors.forename: Rocío
authors.initials: R
authors.lastname: Casado
authors.affiliation: Section of Pediatric Immunodeficiency Diseases, Department of Pediatrics, University Hospital 12 de Octubre, Universidad Complutense de Madrid and Instituto de Investigación Hospital 12 Octubre, Madrid, Spain.
authors.forename: Luis Ignacio
authors.initials: LI
authors.lastname: González-Granado
mesh_terms: D002675:Child, Preschool; D003882:Dermatomyositis / Q000188:drug therapy*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage*; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D011241:Prednisone / Q000627:therapeutic use
chemical_list: D005938:Glucocorticoids; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D011241:Prednisone